<DOC>
	<DOCNO>NCT00011479</DOCNO>
	<brief_summary>The purpose study measure blood level abacavir child adolescent period time follow single dose dosage adolescent determine . Little known abacavir clear body adolescent . It show young child require high abacavir dose base weight adult . Older child , adolescent , may require high dose . This study may provide information whether child 's dose adult dose good HIV-infected adolescent .</brief_summary>
	<brief_title>Blood Levels Abacavir After One Dose HIV-Infected Children Adolescents</brief_title>
	<detailed_description>Pharmacokinetic difference child adult result recommended dos abacavir base weight higher child adult . There insufficient data determine whether pediatric adult dose appropriate HIV-infected adolescent patient . This study measure pharmacokinetic data abacavir adolescent population appropriate dosage determine . Patients evenly enrol 2 group base Tanner Stage . Group I patient Tanner Stage 1 2 ( pre-pubertal ) . Group II patient Tanner Stage 3 , 4 , 5 ( pubertal ) . Each patient receive single oral dose abacavir give commercially available oral solution . Pharmacokinetic blood sample collect dose 0.5 , 1.0 , 1.5 , 2.0 , 2.5 , 3.0 , 4 , 6 , 8 hour post dose abacavir concentration .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are 9 18 year age . Are HIVpositive . Have CD4 cell count 200 cells/microL . Have viral load ( level HIV blood ) 100,000 copies/ml . Have change antiHIV drug 4 week study entry . Are able swallow study medication . Both male female , agree use barrier method birth control 3 day take abacavir dose study . ( This study change . In early version , birth control need . ) Can follow participate Pediatric AIDS Clinical Trials Unit ( PACTU ) entire study . Provide write consent parent guardian , 18 year age . Exclusion Criteria Patients eligible study : Have liver kidney problem , show screening test . Have medical surgical problem affect movement absorption stomach gut . Have opportunistic ( AIDSrelated ) serious bacterial infection require medicine time enrollment . Have disease ( HIV infection ) finding , investigator 's opinion , might make harmful patient study . Have history chronic alcohol use . Fall outside certain weight range age . Are pregnant breastfeeding . Are receive receive abacavir . Are receive nonnucleoside reverse transcriptase inhibitor , include efavirenz , delavirdine , nevirapine ; hydroxyurea ; mycophenylate ; rifampin , rifabutin , anticonvulsant , drug affect liver ; chemotherapy active cancer . Have receive interferon , interleukin , HIV vaccine , experimental therapy within 30 day enter study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Administration , Oral</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>abacavir</keyword>
</DOC>